AOD-9604
What to know about AOD-9604
AOD-9604 is a modified fragment of human growth hormone residues 176-191, developed to isolate metabolic effects without full growth-hormone activity.
- How it may work
- Rodent work proposed effects on fat breakdown and fat formation, but the responsible human pathway and meaningful clinical effect were not established.
- What research found
- The large OPTIONS development study did not produce a statistically significant weight difference versus placebo. Detailed trial results were not published in a peer-reviewed primary report.
- What is not settled
- FDA reports limited safety information, possible immune-reaction and impurity risks, and serious event reports with unclear causality.
- Research and product status
- AOD-9604 is not a licensed U.S. medicine. Its abandoned weight-development program is stronger negative evidence than marketing summaries usually acknowledge.
Research reference
- Research amount range
- 250–500 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Oral in the cited evidence; formulation matters.
- Model accumulation timescale
- ~2 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- FDA's evidence review describes a large 24-week obesity study that did not show a statistically significant weight-loss difference from placebo. It therefore supplies no supported time-to-result window.
- When to assess
- A longer wait cannot be inferred to rescue a negative 24-week result. Early scale movement also cannot establish that AOD-9604 caused the change without a controlled comparison.
- Conditions and limitations
- No controlled evidence establishes a necessary fasting window, exercise timing, injection location, or stacking partner that converts the negative human outcome into a reliable effect.
- When to stop
- No validated target, maintenance phase, or quit rule exists. Extending or increasing exposure because nothing happened during a commonly discussed run is not supported by the human study.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C78H123N23O23S2
- Mol. weight
- 1,815.1 Da
- CAS
- 221231-10-3
- PubChem CID
- 71300630
External references
Roughly 20-30 minutes in published work.
The two human trials of AOD-9604 were oral and one failed at every amount; the subcutaneous figures in circulation are community-derived, not the trial amounts, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- AOD-9604 obesity study (Metabolic Pharmaceuticals)A phase-2 oral study of the hGH fragment did not separate from placebo on weight.